+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07782164

Evaluating Irreversible Electroporation for Treating Recurrent Pelvic Tumors Not Suitable for Other Local Treatments

Led by Amsterdam UMC, location VUmc · Updated on 2026-08-28

27

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the short- and long-term effects of irreversible electroporation IRE in adults over 18 years old who have recurrent pelvic tumors that cannot be treated with surgery, thermal ablation, or radiotherapy. This observational cohort study uses a registry combining past and new patient data to understand if IRE is safe and effective for controlling tumor recurrence in this population. The study includes retrospective data collected from December 2012 through April 2025 and will continue prospectively with new cases thereafter. Participants undergo the IRE procedure, which involves applying electrical pulses to destroy tumor cells without using heat. The treatment duration ranges from 30 minutes to 2 hours during the actual procedure. Participants provide data through routine clinical care, including imaging scans and follow-up assessments. Researchers monitor adverse events and nerve injuries for up to 5 years after treatment. They also track survival outcomes and tumor progression over a period of up to 10 years, aiming to understand safety and long-term effects of IRE for recurrent pelvic tumors.

CONDITIONS

Brief Title

Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)

Research Team

S

Sonia Triggiani, Radiologist

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here